Tag:
Procrit
Latest Headlines
Latest Headlines
Pharma gets its close-up in new Hollywood films
Pharma films are all the rage in Hollywood these days--and several more are on the horizon. After "Love and Other Drugs" turned Jake Gyllenhaal into a Viagra rep and "Contagion" made a vaccine
Medicare affirms rule expected to erode Epogen sales
As expected, Medicare has changed its kidney-care guidelines to remove a requirement that helped fuel sales of Amgen's ( $AMGN ) anemia drug Epogen . Kidney dialysis providers were previously told to
CMS pitches new rules for Amgen anemia meds
Medicare officials may continue to pay for Amgen and Johnson & Johnson's big anemia drugs. But they may also change kidney-care guidelines that affect use of those treatments. As Reuters reports,
Anemia meds didn't work as hoped in heart attack study
Animal studies suggested that the anemia drugs sold by Amgen and Johnson & Johnson might reduce damage in patients who had heart attacks. But new research in the Journal of the American Medical
CMS keeps current anemia drug rules--for now
When is no decision a good decision? When you're Amgen, and the Centers for Medicare and Medicaid Services decides not to change reimbursements for key anemia drugs. At least not for now; the agency
FDA panel to weigh Amgen, J&J drug limits
Once again, FDA's experts will wrangle over safe use of Amgen and Johnson & Johnson's blockbuster anemia drugs. In the wake of a study that raised new questions about the safety of Amgen's
Drug/vial lamellae drive Amgen, J&J anemia-drug recalls
Anemia drugs Procrit and Epogen interact with glass vials over time to produce glass flakes, and that has led to an Amgen recall of the parenteral. The recalled lots were old, and the glass flakes,
Amgen, J&J recall anemia treatments
Amgen and Johnson & Johnson are recalling their Epogen and Procrit anemia treatments because of the potential for barely visible glass flakes in vials containing the injectable medicines. Report
Supremes let J&J whistleblower suit stand
The Supreme Court refused to consider a Johnson & Johnson subsidiary's challenge to a whistleblower lawsuit alleging that it defrauded Medicare by offering kickbacks to health-care providers for
Medicare mulls new restrictions on anemia meds
In a move that could further cut the sales of Amgen and Johnson & Johnson's pricey anemia drugs, the Centers for Medicare and Medicaid Services are reviewing their use to treat patients with
